Kyowa Hakko Kirin Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kyowa Hakko Kirin Company Limited with three other
companies in this sector in Japan:
Mitsubishi Tanabe Pharma Corp
sales of 423.98 billion Japanese Yen [US$3.99 billion]
of which 74%
was Domestic Ethical Drug),
Taisho Pharmaceutical Holdings Co Ltd
(279.77 billion Japanese Yen [US$2.63 billion]
of which 64%
was Self-medication), and
Shionogi & Co Ltd
(338.89 billion Japanese Yen [US$3.19 billion]
of which 100%
During the year ended December of 2017, sales at
Kyowa Hakko Kirin Company Limited were ¥353.38 billion (US$3.33 billion).
increase of 3.0%
versus 2016, when the company's sales were ¥343.02 billion.
Despite this increase, sales are still
below the level achieved in 2015, when Kyowa Hakko Kirin Company Limited
reported sales of ¥364.32 billion.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Kyowa Hakko Kirin Company Limited had sales
of ¥333.16 billion.